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ABSTRACT 
Background. Research has raised significant concern regarding the affective consequences of 
synthetic drug use. However, little evidence from well-controlled longitudinal studies exists on 
these consequences. The aim of this study is to determine whether use of meth/amphetamine 
(speed) and ±3,4-Methylenedioxymeth-amphetamine (MDMA, ecstasy) is independently 
predictive of subsequent depressive symptoms in adolescents.  
Methods. A sample of 3880 adolescents from secondary schools in disadvantaged areas of 
Quebec, Canada, were followed over time (2003–2008). Logistic regression was used to test the 
association between meth/amphetamine and MDMA use in grade 10 (ages 15-16) and elevated 
depressive symptoms on an abridged CES-D scale in grade 11, controlling for pre-existing 
individual and contextual characteristics. 
Results. After adjustment, both MDMA use (odds ratio, 1.7; 95% confidence interval, 1.1–2.6) 
and meth/amphetamine use (odds ratio, 1.6; 95% confidence interval, 1.1–2.3) in grade 10 
significantly increased the odds of elevated depressive symptoms in grade 11. These relationships 
did not vary by gender or pre-existing depressive symptoms. Increased risk was particularly 
observed in concurrent usage (odds ratio, 1.9; 95% confidence interval, 1.2–2.9).  
Conclusions. Adolescent use of meth/amphetamine and MDMA (particularly concurrent use) is 
independently associated with subsequent depressive symptoms. Further inquiry must determine 
whether these associations reflect drug-induced neurotoxicity and whether adolescence is a 
period of increased vulnerability to the hazards of synthetic drug exposure.     
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PROSPECTIVE ASSOCIATIONS BETWEEN METH/AMPHETAMINE (SPEED) AND 
MDMA (ECSTASY) USE AND DEPRESSIVE SYMPTOMS IN SECONDARY SCHOOL 
STUDENTS   
 
INTRODUCTION 
Meth/amphetamine (speed) – i.e. amphetamine or the more prevalent and potent 
methamphetamine – and ±3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) are ranked 
among the most popular illicit drugs consumed by youth in North America and worldwide. 
Although the use of these two types of drugs is particularly widespread among young club/rave 
goers in the dance scene,1 it has also become commonplace in the general population.2 Trends 
over the past 20 years show increased initiation and regular use among adolescents.3 The 
concurrent use of meth/amphetamine and MDMA is typical among recreational users and often 
occurs in the same drug-taking episode, either intentionally or not (through tablet impurity).4,5  
 
Over the past two decades, clinicians and researchers have become increasingly concerned about 
the putative consequences of meth/amphetamine and MDMA use. Animal models suggest 
neurotoxicity in response to large doses of MDMA and meth/amphetamine.5 In humans, research 
suggests potential neurological and functional impairments, notably with regards to the 
development of depressive symptomatology.6-9 Neurotoxicity from the two substances on 5-HT 
neurotransmission could be involved, given that low 5-HT functioning is a trademark biological 
marker of clinical depression.6 The associated depressive outcomes of synthetic drug use in 
adolescents are particularly disconcerting. First, the brain undergoes a period of extensive 
neuronal maturation during adolescence, which opens a window of vulnerability to the 
neurotoxic effects of drug use, even at low doses and frequencies.10 Second, depressive 
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symptoms in adolescence can potentially disrupt normative development and foster delays in 
social, emotional, and/or cognitive development.11  
 
Nonetheless, relatively little research on the relation between MDMA and meth/amphetamine use 
and depressive symptoms in adolescents has been published.12-14 Existing research has been 
mostly cross-sectional, although a few recent longitudinal studies provide evidence in support of 
a relation.12,13,15 Confounding factors have been identified as important limitation of most 
previous studies, in particular pre-existing characteristics and more general drug use.7,16 For 
example, synthetic drug users may have elevated depressive symptoms that precede rather than 
follow their drug use.  Meth/amphetamine and MDMA use have also typically been considered 
separately, despite the frequent concurrent use and putative additive or interactive noxious effects 
of these drugs.  
 
In this study, a population-based, longitudinal sample of typically developing adolescents was 
used to examine the prospective relationship between meth/amphetamine use and MDMA use in 
tenth grade and subsequent elevated depressive symptoms in eleventh grade. The separate and 
concurrent consumption of these drugs were considered. In order to secure unbiased estimates, 
our analytic strategy considers pre-existing individual and contextual factors, including 
antecedent depressive symptoms and the concurrent use of other substances.  
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METHODS 
Participants 
Participants are from the New Approaches New Solutions (NANS) longitudinal data set (2003–
2008). A stratified random sampling strategy was designed to select schools representative of all 
schools in disadvantaged areas of Quebec in terms of geographical location and size. The initial 
sample for this study comprises 6126 students from 57 low SES French-language secondary 
schools across the province of Quebec (Canada). Most participants (n=5055) were followed from 
grades 7 to 11 which correspond to the first and last year of secondary school in Quebec. A 
subset (n=1071) was followed from eighth grade. Consent was obtained for 77% of the eligible 
participants. The NANS sample is mostly Caucasian (91.3%) and approximately represented by 
gender (54.4% females). For the present study, the sample included all students aged 15 or 16 
with available data in grade 10, as well as available data at baseline, in either grade 7 or 8. 
(n=3880). Follow-up data in grade 11 from these participants were also used as part of study 
design. A total of 2161 participants (55.7%) were available at follow-up in grade 11. Missing 
data on background variables collected at grades 7-8 ranged from 0% to 22.5%. Written informed 
consent was obtained with signatures from all parents and participants. All self-reported 
questionnaires were administered in class by trained and supervised experimenters. All data 
collection procedures obtained IRB approval by the University of Montreal.  
 
The fact that a proportion of the participants who were part of the initial NANS sample at the 
beginning of secondary school were excluded based on data non-availability in grade 10 has 
implications for sample representativity. The reasons for data non-availability in grade 10 are 
largely similar to the reasons related to sample attrition from grade 10 to 11. The data analysis 
section details these reasons and also shows a comparison between study dropouts and 
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participants who remained in the sample. As will be seen, study dropouts were globally at higher 
risk than individuals who remained in the study and for this reason, the final sample should be 
considered of overall lower risk than the initial NANS population at the beginning of secondary 
school.  
 
Measurement of MDMA use and meth/amphetamine use 
MDMA use and meth/amphetamine use were assessed in grade 10 using the following items: 
“Have you ever used ecstasy (MDMA)?” and “Have you ever used speed (amphetamines)?”. The 
response scale for these items was never (0); yes, in my lifetime (1); yes, in the past year (2); and 
(3) yes, in the past month. Past-year use was obtained by coding the latter two categories as 1 (= 
yes), and by coding the first two categories as 0 (= no). Both estimates were also combined to 
create a four-category variable, in the form of three dummy variables representing MDMA use 
alone, meth/amphetamine use alone, and use of both meth/amphetamine and MDMA. 
 
Measurement of outcome variable: elevated depressive symptoms 
Depressive symptoms were measured in grade 11 using an abridged version of the Center for 
Epidemiologic Studies-Depression (CES-D) questionnaire.17  The 16-item abridged scale assesses 
how individuals felt or behaved in the past week (alpha = .89). Each item is answered on a 4-
point scale, ranging from “rarely or none” to “most or all”. The scale has been validated for use 
with adolescents.18 To capture symptom severity, depressive symptoms were divided into two 
categories of “elevated” and “low” symptoms using a total score cut off at 16 or beyond. This 
cut-off approximately corresponds to 1-SD above the mean as well as the 85th percentile of 
depressive symptoms in grade 11. This yielded a proportion of participants with “elevated 
symptoms” which corresponds to depression prevalence estimates observed in adolescents.19  
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Measurement of potential confounders 
Concurrent Use of Other Substances.  
Students provided an assessment of concurrent general substance use with MDMA and 
meth/amphetamine use in grade 10. Frequency of alcohol use and frequency of marijuana use in 
the past year were assessed using a 7-point scale ranging from “never” to “more than 60 times”. 
The use of hard drugs (“heroin, morphine, opium, crack, etc”) in the past year and cigarette use in 
the past 30 days were assessed as dichotomous measures (no use; any use).  
 
Pre-existing Individual and Contextual Characteristics.  
Individual, family, and peer characteristics of participants were considered as controls prior to 
MDMA use and meth/amphetamine use. When possible, mean scores in grades 7-8 were used to 
obtain more stable characteristics and reduce missing data (available score was used when one 
data point was missing). Pre-existing depressive symptoms were measured with the same 
abridged CES-D scale (alpha = .92) as the outcome measure. Affective engagement to school was 
measured using 6-item scale rated on a 7-point Likert scale (alpha = .83).20 School anxiety was 
measured using a 6-item scale (alpha = .82), mostly composed of items from Spence’s anxiety 
questionnaire.21 Participants rated statements on a 4-point scale. Academic achievement was 
measured as a mean score of self-reported grades in Language arts (French) and mathematics. 
Grade retention was dichotomously coded as participants who were not at an age-appropriate 
level (i.e. participants who were 1 year behind or in a special class) in grade 7 or 8 (=1) as 
opposed to participants who were (=0). Delinquency was measured using a 16-item scale 
investigating delinquent behaviors in the past year (alpha = .94), rated on a 4-point scale.22 
General intelligence was measured using the Standard Raven Progressive Matrices for 
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adolescents at first data collection for each participant.23 The conscientiousness subscale of the 
Big Five Inventory24 (alpha = .75) was used as a proxy reflecting planning and socially 
appropriate inhibitory control aspects of executive functioning.25 Participants rated 9 items on a 
4-point scale.  The scale was not available in grades 7-8 and was rather considered as a stable 
individual characteristic in grade 10.  
 
Contextual controls were variables related to the family and peers of participants. Family 
variables included conflict with parents (3-item scale, alpha =.79), positive communication with 
parents (6-item scale, alpha =.88), and parental rules (7-item scale, alpha =.71).22 Information was 
also collected at first data collection for each participant about maternal education (0 = no high 
school degree; 1 = high school or higher), intact/nonintact household (0 = parents together; 1 = 
parents separated), and parental occupational prestige (mean of mother and father score).26 Three 
peer controls were included: (1) Drug use by closest friends (1 = yes; 0 = no); (2) Social isolation 
(5-item on a 4-point Likert scale, alpha =.86); and (3) Peer social support (4-item on a 5-point 
Likert scale, alpha =.86).22  
 
Data analysis 
Logistic regression, estimated with maximum likelihood (ML), was used to model the unique 
contribution of MDMA and meth/amphetamine use in grade 10 in predicting subsequent elevated 
depressive symptoms (CES-D score of 16 or above) in grade 11. First, the separate contribution 
of MDMA use (Model 1) and meth/amphetamine use (Model 2) in predicting elevated depressive 
symptoms were tested. Second, MDMA and meth/amphetamine use were investigated together 
(Model 3) by creating three mutually exclusive predictors: MDMA use alone, meth/amphetamine 
use alone, and concurrent use (use of both substances, whether in the same drug-taking episode or 
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not). Model 3 was selected over a model assessing the relative prediction of MDMA and meth 
use because the two variables were highly correlated and their simultaneous inclusion as 
independent predictors yielded unstable estimates with large standard errors. Model 3 resolved 
this issue and also offered the advantage of directly assessing the risk associated with this 
concurrent use of both substances for subsequent depressive symptoms. Unadjusted and adjusted 
versions each model were fitted. Adjusted versions included controls for (1) pre-existing 
individual and contextual characteristics at baseline (grades 7-8) and (2) concurrent use of other 
substances in grade 10 (frequency of alcohol and cannabis use, cigarette use, and hard drugs use). 
Adjusted models were estimated adjusting for the within-school variance tied to the nested 
design. Information on the link between control variables and the outcomes can be found in 
Appendix 1 (Web Only File).  
 
Attrition in grade 11 was associated with MDMA use (χ21 = 27.9, p < .001) and 
meth/amphetamine use (χ21 = 9.7, p = .002) in grade 10, as well as depressive symptoms in grades 
7-8 (t3878 = 2.39, p = .02), suggesting a potential attrition bias. Further information can be found 
in Appendix 2 (Web Only File). Multiple imputation was used since it has been shown to reduce 
attrition bias, especially when the outcome variable is available at multiple time points.27 The 
imputation was conducted with NORM.28 All study variables, including interaction terms, were 
included in the imputation model. Twenty different datasets were imputed and results are 
averages of parameters in models fitted on all datasets using Mplus version 5.1.29 For validation 
purposes, models 1 to 3 were replicated with continuous CES-D scores and both dichotomous 
and continuous versions were also fitted on the non imputed dataset. Results were largely similar 
in terms of direction and significance in all validation models.  
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RESULTS 
Descriptives 
Prevalence of MDMA use and meth/amphetamine use in grade 10 and elevated depressive 
symptoms in grade 11 are reported in Table 1. Meth/amphetamine use was more prevalent than 
MDMA use. Use of both meth/amphetamine and MDMA (6.7%) was more prevalent than 
meth/amphetamine use alone (4.9%) and MDMA use alone (1.3%). There were no gender 
differences in the prevalence of meth/amphetamine use and MDMA use in grade 10, as well as 
elevated depressive symptoms in grade 11 (CES-D score of 16 or above). 
 
 
 
Table 1. Prevalence of MDMA and Meth/amphetamine Use in Grade 10 and Elevated Depressive 
Symptoms in Grade 11 
 n (%) a 
 Females  Males  Total 
MDMA use 152 (7.2)  158 (8.9)  310 (8.0) 
Meth/amphetamine use 236 (11.2)  215 (12.1)  451 (11.6) 
Elevated Depressive Symptoms b 326 (15.5)   258 (14.6)   584 (15.1) 
a Prevalences were derived from the first imputed dataset: Females (n = 2210), Males (n = 1770), Total (n= 3880). 
b Center for Epidemiologic Studies-Depression (CES-D) score of 16 or above. 
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Prediction of depressive symptoms by MDMA use and meth/amphetamine use 
Table 2 reports the association between meth/amphetamine use and MDMA use in grade 10 and 
subsequent elevated depressive symptoms (CES-D score of 16 or above) in grade 11. Models 1 
and 2 show that both MDMA use and meth/amphetamine use significantly increased the odds of 
having elevated depressive symptoms the following year. These relationships remained 
significant after adjusting for a series of pre-existing individual and contextual characteristics, 
including depressive symptoms at baseline, as well as the concurrent use of other substances. 
After adjustment, MDMA users and meth/amphetamine users were respectively 1.7 times and 1.6 
times more likely than non-users to report elevated depressive symptoms the following year. 
Relative to other variables, these associations made the largest contributions toward predicting 
depressive symptoms after baseline school anxiety and depressive symptoms (though within the 
range of other significant controls). 
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Table 2. Association Between Meth/amphetamine and MDMA use in Grade 10 and Elevated 
Depressive Symptoms in Grade 11 
   Elevated Depressive Symptomsa, OR (95% CI) 
   Unadjusted  Adjusted b 
Model 1    
 MDMA use 2.4 (1.6 - 3.5)c  1.7 (1.1 - 2.6)c 
Model 2    
 Meth/amphetamine use 2.1 (1.5 - 2.9)c  1.6 (1.1 - 2.3)c 
Model 3    
 Meth/amphetamine use only 1.7 (1.1 - 2.7)c  1.4 (0.8 - 2.4) 
 MDMA use only 2.1 (0.9 - 5.0)  1.5 (0.6 - 4.1) 
  Concurrent use 2.5 (1.6 - 3.8 )c   1.9 (1.2 - 2.9)c 
Abbreviations: OR, Odds Ratio; CI, Confidence Interval. 
a Center for Epidemiologic Studies-Depression (CES-D) score of 16 or above. 
b Adjusted for the use of other substances in grade 10 (frequency of alcohol Use, frequency of marijuana use, hard 
drugs use, cigarette use), conscientiousness in grade 10, and pre-existing individual and contextual characteristics in 
grades 7-8 (depressive symptoms, affective engagement to school, school anxiety, academic achievement, grade 
retention, delinquency, intelligence, conflict with parents, positive communication with parents, parental rules, 
maternal education, intact/non intact household, parental occupational prestige, drug use by best friends, peer social 
support, social isolation). 
c Significant findings. 
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Model 3 was aimed at better circumscribing the unique and combined contributions of 
meth/amphetamine use and MDMA use in predicting the outcome. Before adjustment, both 
concurrent users and meth/amphetamine only users were significantly more likely than non-users 
of being in the upper end of depressive scores. However, only combined use of MDMA and 
meth/amphetamine remained significantly associated with subsequent elevated depressive 
symptoms after adjusting for confounders. After adjustment, combined users were 1.9 times more 
likely than non-users to report elevated depressive symptoms the following year. Non 
significance of MDMA and meth/amphetamine use only should be considered with caution, 
given the low prevalence within these categories (below 5%).  
 
Because somatic symptoms could reflect transient effects of concurrent drug use in grade 11 
rather than long-term depressive symptoms per se,16 the above models were replicated using a 
measure of depressive symptomatology without the 5 somatic CES-D subscale items.18 Results of 
all models were unchanged by this modification of the outcome measure.  
 
Finally, supplementary moderation analyses were undertaken to examine the possibility that the 
prediction of MDMA and meth/amphetamine use could vary by gender30 or pre-existing 
depressive symptoms - consistent with a stress-diathesis view in which vulnerable individuals 
would be more affected by drug use.31 Models 1 and 2 were replicated with interaction terms of 
MDMA use and meth/amphetamine use by gender, and by pre-existing depressive symptoms 
respectively. These terms were not statistically significant in any of the replicated models.  
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DISCUSSION 
MDMA and meth/amphetamine use in grade 10 predicted depressive symptoms one year later, 
independent of a number of important individual and contextual controls. This finding is 
consistent with animal and human studies suggesting long-term negative influences of synthetic 
drug use.8,9 Our results provide, to the best of our knowledge, the first compelling evidence that 
recreational MDMA and meth/amphetamine use places typically developing secondary school 
students at greater risk of experiencing depressive symptoms.  
 
Compared to non-users, MDMA users and meth/amphetamine users in grade 10 were 1.7 and 1.6 
times more likely to report depressive symptoms the following year, respectively. This 
association was not just an artefact of somatic symptoms found in the CES-D scale, which could 
reflect transient symptoms of drug use rather than longer-term affective outcomes.16 Contrary to 
earlier suggestions,30,31 this association did not vary by gender or antecedent depressive 
symptoms.     
 
Further investigation indicated that concurrent meth/amphetamine and MDMA use (i.e. use of 
both substances, whether in the same drug-taking episode or not) accounted for most of the 
predictive power between the use of these drugs and subsequent depressive symptoms. This 
suggests additive or synergistic adverse effects of concurrent MDMA and meth/amphetamine 
use. Animal studies indicate that damage from MDMA and methamphetamine use can be 
synergistically enhanced by their concurrent use, especially within the same consumption 
episode.5 Many recreational users engage in simultaneous drug mixing and these users may be 
particularly at risk of developing negative affective consequences.5 Although some users may 
have developed a specific preference for one or the other, concurrent users might be more 
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experienced or heavier users in contrast to MDMA or meth/amphetamine only users, who might 
be “recent initiators” or “experimenters.” As such, our concurrent use variable could reflect 
adverse effects of both multiple drug use and of frequent and/or cumulative use. However, 
because this variable could primarily capture the intensive use of one substance more than the 
other and also because of the low prevalence of MDMA only and meth/amphetamine only use in 
our sample, it would be premature to discard the notion that MDMA or meth/amphetamine use 
has specific adverse effects.  
 
The contribution of MDMA and meth/amphetamine use (in particular concurrent usage) to the 
prediction of subsequent depressive symptoms is relatively modest, but remarkable enough to be 
interpreted as nontrivial. Modest contributions can have significant clinical implications from a 
population-health perspective. This may be especially true in this case, given that drug-related 
consequences were considered in a low risk sample of youth at a time when the large majority of 
users were probably early in their trajectory of use. Depressive symptoms can influence delays or 
impediments in developmental milestones and social and occupational functioning.11 Any 
potential contribution of MDMA and meth/amphetamine use toward depressive symptoms should 
be taken seriously considering the risk of drug-induced neurotoxicity. Hence, from a cumulative 
risk perspective, adding the use of these drugs to the typical challenges and crises of adolescence 
might chart a life-course toward poorer mental health prognosis.  
 
In addition to a prospective-longitudinal design, the main strength of this study was 
comprehensive control for important confounds that have not been consistently considered in 
previous work. A large number of individual and contextual characteristics antecedent to MDMA 
and meth/amphetamine use were included, particularly pre-existing depressive symptoms, and 
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the use of other substances. Significant controls mainly reflected pre-existing psychological 
vulnerabilities (depressive symptoms, school anxiety) or individual difficulties (low 
conscientiousness, delinquency, and grade retention), reinforcing the need to control for such 
factors.7 Surprisingly, none of the substance use controls predicted subsequent depressive 
symptoms in our models, contradicting results from previous studies involving cannabis in 
particular.32 Nevertheless, findings have been mixed and typically depend on temporal and 
measurement factors.33  
 
This study is not without limitations. First, despite our extensive control for other drug use, 
additive or interactive effects of meth/amphetamine and MDMA use coupled with other drugs 
cannot be ruled out.16 Second, all measures were self-reports, which is both a strength and 
limitation. The exact content of tablets sold as MDMA or meth/amphetamine eludes users,16 even 
if support exists for the validity of self-reported substance use.34 Third, attrition also poses a 
threat as in most longitudinal studies. Our confidence is reinforced by the fact that incomplete 
data were imputed and the direction and significance of results were largely similar with and 
without imputation.  
 
Future research needs to better define which parameters of synthetic drug use matter most in 
predicting depressive outcomes in terms of frequency, quantity, trajectory and/or context of use. 
This includes specifying exactly how the concurrent use of these drugs increases the risk of such 
outcomes. Research that determines whether adolescent-onset versus adult-onset use has distinct 
associations with the development of depressive symptomatology, both at the neurobiological 
and functional levels, is also warranted. Longitudinal data, particularly mixed biological and self-
report, are most desirable to achieve this purpose.  
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This study has important public health implications for adolescent populations. More evidence is 
still needed to secure more causal interpretations of meth/amphetamine and MDMA use in the 
development of depressive symptoms, and to determine the role of drug-induced 5-HT 
neurotoxicity. Nevertheless, our results concur with others and imply a ‘principle of caution’ in 
messages targeting adolescents, upholding that MDMA and meth/amphetamine use, particularly 
when concurrent, likely increases the risk of experiencing disruptions in affective 
symptomatology.  
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Box	1.		
What	is	already	known	on	this	subject?	
• The	use	of	the	synthetic	drugs	MDMA	(ecstasy)	and	meth/amphetamine	(speed)	tends	to	be	
associated	with	elevated	depressive	symptoms	in	adults.		
• However,	the	existence	and	nature	of	this	association	in	adolescents	remains	unclear.	
	
What	this	study	adds?	
• This	study	provides	evidence	that	the	use	of	MDMA	(ecstasy)	and	meth/amphetamine	(speed)	
predicts	subsequent	depressive	symptoms	in	adolescents	beyond	important	individual	and	
contextual	confounders,	including	prior	depressive	symptoms	and	the	use	of	other	drugs.		
• This	suggests	that	synthetic	drug	use	presents	long-term	risks	for	affective	disturbance.	
	
 
